Clinical Study
Loss to Followup in HIV-Infected Patients from Asia-Pacific Region: Results from TAHOD
Table 2
Patient characteristics.
| Total | 3626 | | Characteristics | Number | % |
| Sex | | | Male | 2567 | 71 | Female | 1059 | 29 |
| Current age (years) | | | ≤35 | 1383 | 38 | 36–45 | 1449 | 40 | 46+ | 794 | 22 |
| Reported exposure | | | Heterosexual contact | 2337 | 64 | Homosexual contact | 749 | 21 | Injecting drug use | 263 | 7 | Other/unknown | 277 | 8 |
| Ethnicity | | | Chinese | 989 | 27 | Indian | 390 | 11 | Thai | 933 | 26 | Other/unknown | 1314 | 36 |
| Baseline CD4 count (cells/μl.) | | | ≤100 | 239 | 7 | 101–200 | 406 | 11 | 201+ | 2531 | 70 | Missing | 450 | 12 |
| Baseline HIV RNA (copies/ml) | | | ≤500 | 1482 | 41 | 501+ | 379 | 10 | Missing | 1765 | 49 |
| CDC disease stage at baseline | | | Stage A | 1621 | 45 | Stage B | 321 | 9 | Stage C | 1684 | 46 |
| Tuberculosis diagnosis at baseline | | | No | 2758 | 76 | Yes | 868 | 24 |
| Time since HIV infection (years) | | | ≤5 | 2295 | 63 | 6+ | 1246 | 34 | Missing | 85 | 2 |
| Hepatitis B infection | | | No | 2297 | 63 | Yes | 257 | 7 | Not tested | 1072 | 30 |
| Hepatitis C infection | | | No | 2007 | 55 | Yes | 324 | 9 | Not tested | 1295 | 36 |
| Anemia at baseline | | | No | 2480 | 68 | Yes | 597 | 16 | Haemoglobin not tested | 567 | 16 | Antiretroviral treatment at baseline | | | 3 + (NRTI + NNRTI) | 2224 | 61 | 3 + (NRTI + PI) | 744 | 21 | No/mono/double drug | 583 | 16 | 3 + (other combination) | 75 | 2 |
|
|
Anemia: haemoglobin <13 g/dl (male), <11 g/dl (female); NRTI: nucleoside reverse transcriptase inhibitor; NNRTI: nonnucleoside reverse transcriptase inhibitor; PI: protease inhibitor.
|